LFG
ABUS icon

Larson Financial Group’s Arbutus Biopharma ABUS Stock Holding History

Larson Financial Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44K Hold
716
– – ﹤0.01% 2921
2026
Q1 		$3.22K Sell
716
-45
-6% -$197 ﹤0.01% 2794
2025
Q4 		$3.66K Buy
761
+22
+3% +$99 ﹤0.01% 2580
2025
Q3 		$3.35K Buy
+739
New +$2.71K ﹤0.01% 2506
2021
Q1 		– Sell
-901
Closed -$3K – 820
2020
Q4 		$3K Buy
+901
New +$3.15K ﹤0.01% 591

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Larson Financial Group's ABUS Position: Q2 2026 in Review

Larson Financial Group held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 716 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

Larson Financial Group first reported a position in ABUS in Q4 2020 and has held it in 5 quarters since. The position peaked at $3.66K in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Larson Financial Group held 716 shares of Arbutus Biopharma worth $3.44K as of Q2 2026.
  • Larson Financial Group left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2921 holding.
  • Larson Financial Group first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 5 quarters since.
  • Larson Financial Group's Arbutus Biopharma position peaked at $3.66K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.